Drug Database · Clinicians

Sitagliptin

Brands (131) Kozta, Adivia, Januvia…Show all
Kozta · Adivia · Januvia · Sitaglinex · Taglisyd · Xelevia · Acantha · Astaliptin · Diagliptin · Diawell · Gliptadin · Gliptalife · Gliptins · Glipzeal · Glyxera · Janogen · Januvis · Jentin · Lupigliptin · Medliptin · Si2norm · Sitadin · Sitagen · Sitagligo · Sitaglizen · Sitakem · Sitaphil · Sitapro · Sitazuca · Sitfar · Sitzea · Tiglipza · Torsit 100 · Torsit 50 · Trevia · Vilantra · Xglip · Bsita 100 · Bsita 50 · Diaglow-100 · Diaglow-50 · Dialiptin · Dialiptin-100 · Dialiptin-25 · Dialiptin-50 · Diasit 100 · Diasit 25 · Diasit 50 · Diasitzan · Diasutin-100 · Diasutin-50 · Diavel 100 · Diavel 50 · Gliden 100 · Gliden 50 · Glipgen · Gliptadin-100 · Gliptadin-50 · Gliptanova-100 · Gliptanova-50 · GLUCADROP-100 · Glucadrop-50 · Glukex-100 · Glukex-50 · Gluviance · Glysiptin · Instadip 100 · Instadip 25 · Instadip 50 · Januglip 100 · Januvit 100 · Januvit 50 · Jestaglip 100 · Jestaglip 50 · philsitz-100 · Philsitz-50 · Premiliptin · Progliptin · Silaptaen 100 · Silaptaen 50 · Sitag-100 · Sitag-50 · Sitagli-100 · Sitagli-50 · Sitaglisaph-100 · Sitaglisaph-50 · Sitaglux 100 · Sitaglux 50 · Sitagpina · Sitagral-50 · Sitagram-100 · Sitagrich · Sitaguard 100 · Sitaguard 50 · Sitalia 100 · Sitallion 100 · Sitallion 50 · Sitamac 100 · Sitamac 50 · Sitarox-100 · Sitarox-50 · Sitastar-100 · Sitastar-50 · Sitathyst 50 · Sitatin 100 · Sitatin 50 · Sitavia 100 · Sitavia 50 · Sitazit 100 · Sitazit 25 · Sitazit 50 · Sitodol 100 · Sitodol 50 · Sitplixin 100 · Sitplixin 50 · Sunglip 100 · Sunglip 50 · SytaGet 50 · Taglipin · Torsit 25 · Volrea · Xiglip · Xigtalptn · Xigtalptn 25 · Xigtalptn 50 · Xordim-50 · Zincretin 100 · Zincretin 50 · Zita 100 · Zita 50 · Zytacare

Dipeptidyl peptidase 4 (DPP-4) inhibitor; Dipeptidyl peptidase 4 Inhibitor/Anti-Diabetic; and others PH FDA category

25 mg/day if eGFR <30 or dialysisRx · Prescription drug216 PH productsVAT-exempt (some products) Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f85a48d0-0407-4c50-b0fa-7673a160bf01, version date November 14, 2024 (JANUVIA · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes (1) JANUVIA has not been studied in patients with a history of pancreatitis.

(1, 5.1) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA. [See Warnings and Precautions (5.1).]

Contraindications

  • History of serious hypersensitivity to sitagliptin (e.g., anaphylaxis, angioedema)
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. [See Warnings and Precautions (5.5); Adverse Reactions (6.2).] History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema (5.5, 6.2)

Dosing: Adult

  • Type 2 diabetes (glycemic control): 100 mg once daily; 50 mg if eGFR 30 to <45; 25 mg if eGFR <30 (including dialysis)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food. (2.1)
  • Dosage adjustment is recommended for patients with eGFR less than 45 mL/min/1.73 m². (2.2)
  • Dosage Adjustment in Patients with Renal Impairment (2.2)
  • eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m² eGFR less than 30 mL/min/1.73 m² (including patients with end stage renal disease [ESRD] on dialysis) 50 mg once daily 25 mg once daily
2.1 Recommended Dosing

2.1 Recommended Dosing The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food.

2.2 Recommendations for Use in Renal Impairment

2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUVIA and periodically thereafter. For patients with an estimated glomerular filtration rate [eGFR] greater than or equal to 45 mL/min/1.73 m² to less than 90 mL/min/1.73 m², no dosage adjustment for JANUVIA is required. For patients with moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m²), the dose of JANUVIA is 50 mg once daily.

For patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.

Dosing: Altered kidney function

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor cleared by the kidneys. The US label lowers the dose to 50 mg daily at an estimated glomerular filtration rate (eGFR) of 30 to 44 and to 25 mg daily below 30 or on dialysis, without regard to dialysis timing.

Kidney function measure: Label uses eGFR (mL/min/1.73 m2).

Show full dosing details
eGFR ≥60
100 mg once daily; no adjustment (label: eGFR ≥45).
eGFR 30–59
eGFR 45–59: 100 mg once daily. eGFR 30–44: 50 mg once daily (label).
eGFR 15–29
25 mg once daily (label).
eGFR <15 (not on dialysis)
25 mg once daily (label).
Hemodialysis (intermittent)
25 mg once daily, without regard to dialysis timing (label).
Peritoneal dialysis
25 mg once daily (label).
CRRT
No data in label.
  • Dialyzable? Modestly: about 13.5% removed over a 3–4 hour hemodialysis session (label).
  • Monitoring Assess kidney function before starting and periodically (label). Pancreatitis, hypoglycemia with sulfonylureas or insulin.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Not established in children.
eGFR 30–59
Not established in children.
eGFR 15–29
Not established in children.
eGFR <15 (not on dialysis)
Not established in children.
Hemodialysis (intermittent)
Not established in children.
Peritoneal dialysis
Not established in children.
CRRT
Not established in children.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUVIA and periodically thereafter. For patients with an estimated glomerular filtration rate [eGFR] greater than or equal to 45 mL/min/1.73 m² to less than 90 mL/min/1.73 m², no dosage adjustment for JANUVIA is required. For patients with moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m²), the dose of JANUVIA is 50 mg once daily.

For patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.

8.6 Renal Impairment Sitagliptin is excreted by the kidney, and sitagliptin exposure is increased in patients with renal impairment. Lower dosages are recommended in patients with eGFR less than 45 mL/min/1.73 m² (moderate and severe renal impairment, as well as in ESRD patients requiring dialysis). [See Dosage and Administration (2.2); Clinical Pharmacology (12.3).]

Patients with Renal Impairment An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment, including patients with ESRD on hemodialysis, as compared to normal healthy control subjects.

Dosing: Pediatric

Approved ages
Safety and effectiveness not established in pediatric patients; pediatric trials (10–17 years) did not show efficacy (label).
Usual dose
Not established.
Maximum dose
Not applicable.
Neonates
Neonates: not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of JANUVIA have not been established in pediatric patients. Three 20-week double-blind, placebo-controlled studies each with 34-week extensions were conducted to evaluate the efficacy and safety of sitagliptin in 410 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes, with or without insulin therapy (HbA1c 6.5-10% for patients not on insulin, HbA1c 7-10% for patients on insulin).

At study entry, patients in study 1 were not treated with oral antihyperglycemic agents; patients in studies 2 and 3 were on maximally tolerated metformin therapy. The primary efficacy endpoint was the change from baseline in HbA1c after 20 weeks of therapy. The pre-specified primary efficacy analyses included data from study 1 and pooled data from studies 2 and 3, regardless of glycemic rescue or treatment discontinuation.

In both efficacy analyses, the effect of treatment with sitagliptin was not significantly different from placebo. In study 1, the mean baseline HbA1c was 7.5%, and 12% of patients were on insulin therapy. At week 20, the change from baseline in HbA1c in patients treated with JANUVIA (N=95) was 0.06% compared to 0.23% in patients treated with placebo (N=95), a difference of -0.17% (95% CI: -0.62, 0.28).

In studies 2 and 3, the mean baseline HbA1c was 8.0%, 15% of patients were on insulin and 72% were on metformin HCl doses of greater than 1,500 mg daily. At week 20, the change from baseline in HbA1c in patients treated with sitagliptin (N=107) was -0.23% compared to 0.09% in patients treated with placebo (N=113), a difference of -0.33% (95% CI: -0.70, 0.05).

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects (N=3884) in pre-approval clinical safety and efficacy studies of JANUVIA, 725 patients were 65 years and over, while 61 patients were 75 years and over. No overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects.

While this and other reported clinical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. Because sitagliptin is substantially excreted by the kidney, and because aging can be associated with reduced renal function, renal function should be assessed more frequently in elderly patients [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].

Dosage forms

Philippines

  • Film-coated tablet: 25 mg, 50 mg, 100 mg
  • Tablet: 25 mg, 50 mg, 100 mg
  • Film c oated tablet: 50 mg

Registered products in the Philippines

216 products registered with the Food and Drug Administration (FDA) Philippines list Sitagliptin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Sitaglipin (as phosphate) (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products216
Philippine FDA-registered products for Sitagliptin
Package insert
AcanthaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-12289-02
Jul 8, 2027
AcanthaSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-12290-02
Jul 8, 2027
AdiviaSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7128
Apr 20, 2031
AdiviaSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7127
Apr 20, 2031
AdiviaSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7129
Apr 20, 2031
AstaliptinSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8900-03
Jun 8, 2030
AstaliptinSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8901-03
Feb 9, 2031
Bsita 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16123
Nov 6, 2029
Bsita 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Limited.India
Genedrift Philippines OPC
DRP-16122
Nov 6, 2029
DiagliptinSitaglipin (as phosphate)Variant spelling
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-12289
Jul 8, 2032
DiagliptinSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12290
Jul 8, 2027
Diaglow-100Sitagliptin (as phosphate monohydrate)`
100 mg Film-Coated TabletAlu/Opaque PVC Foil Blister pack x 10's (Box of 100's)
RxVAT-exempt
Sunglow Lifescience Private LimitedIndia
Macropharma Corporation
DRP-17996
Apr 21, 2031
Diaglow-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Opaque PVC Foil Blister pack x 10's (Box of 100's)
RxVAT-exempt
Sunglow Lifescience Private LimitedIndia
Macropharma Corporation
DRP-17997
Apr 21, 2031
DialiptinSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
J.M. Tolmann Laboratories Inc.Metro Manila
—
DRP-11314
Feb 24, 2032
Dialiptin-100Sitagliptin (as phosphate)
100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.bangladesh
Macropharma Corporation
DRP-13437
Feb 17, 2028
Dialiptin-25Sitagliptin (as phosphate)
25mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.bangladesh
Macropharma Corporation
DRP-13435
Feb 17, 2028
Dialiptin-50Sitagliptin (as phosphate)
50mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Macropharma Corporation
DRP-13436
Feb 17, 2028
Diasit 100Sitagliptin (as hydrochloride monohydrate)
100 mg Film Coated TabletWhite opaque PVC/PVDC-Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited, Formulation Unit - XVIndia
AAA Pharma, Inc.
DR-XY49065
May 2, 2029
Diasit 25Sitagliptin (as hydrochloride monohydrate)
25 mg Film Coated TabletWhite opaque PVC/PVDC-Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited, Formulation Unit - XVIndia
AAA Pharma, Inc.
DR-XY49067
May 2, 2029
Diasit 50Sitagliptin (as hydrochloride monohydrate)
50 mg Film Coated TabletWhite opaque PVC/PVdC-Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited, Formulation Unit - XVIndia
AAA Pharma, Inc.
DR-XY49066
May 2, 2029
DiasitzanSitagliptin
100 mg Film-coated TabletAlu / PVC Opaque White Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical and Pharma Inc.
DRP-16597-01
May 13, 2030
Diasutin-100Sitagliptin (As Phosphate Monohydrate)
100 mg Film Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Suhitas Pharmaceuticals, Inc.
DRP-12958
Nov 9, 2027
Diasutin-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Suhitas Pharmaceuticals Inc.
DRP-8352
Aug 28, 2029
Diavel 100Sitagliptin (as phosphate)
100mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's
RxVAT-exempt
Globela Pharma Private LimitedIndia
Amb HK Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-13265
Jan 18, 2028
Diavel 50Sitagliptin (as phosphate)
50mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 1 blister pack x 10 tablets)
RxVAT-exempt
Globela Pharma Private Limited.India
Amb HK Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-13267
Jan 18, 2028
DiawellSitagliptin (As Phosphate)
100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12548
Aug 31, 2027
DiawellSitagliptin (As Phosphate)
50mg Film-Coated TabletAlu/Alu blister pack x 10's
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12549
Aug 31, 2027
Gliden 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16142
Nov 13, 2029
Gliden 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16141
Nov 13, 2029
GlipgenSitagliptin
100 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16597-03
May 13, 2030
GliptadinSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Medchoice Endocrine Group, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8900-02
Jun 8, 2030
GliptadinSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Medchoice Endocrine Group, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8901-02
Jun 8, 2030
Gliptadin-100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation
DRP-9079-01
Oct 31, 2030
Gliptadin-50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation
DRP-9078-01
Oct 31, 2030
GliptalifeSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box ox of 30's)
RxVAT-exempt
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16655
Jun 10, 2030
GliptalifeSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-19168
Nov 11, 2031
Gliptanova-100Sitagliptin (as phosphate monohydrate)
100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Medinova Pharmaceutical Inc.
DRP-16382
Feb 28, 2030
Gliptanova-50Sitagliptin (as phosphate monohydrate)
50 mg Film Coated TabletsAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Medinova Pharmaceutical Inc.
DRP-16383
Feb 28, 2030
GliptinsSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-9079-03
Oct 31, 2030
GliptinsSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-9078-04
Oct 31, 2030
GlipzealSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu-Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
The ACME Laboratories Ltd.Bangladesh
Novocore Pharma Inc.Importer: Euro Generics International Phils., Inc.
DR-XY45081
Feb 16, 2031
GlipzealSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The ACME Laboratories Ltd.Bangladesh
Novocore Pharma Inc.Importer: Euro Generics International Phils., Inc.
DR-XY45080
Feb 16, 2031
GLUCADROP-100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceutical LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc.
DRP-6382-03
Oct 9, 2030
Glucadrop-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: MedEthix, Inc.
DRP-6383-03
Oct 9, 2030
Glukex-100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medlink Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-9079
Oct 31, 2030
Glukex-50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medlink Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-9078
Oct 31, 2030
GluvianceSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Rule Med Pharma Corp.Importer: Pharmakon Biotec, Inc.
DRP-13645-07
Mar 22, 2028
GlysiptinSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu / White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Totalcare Pharma Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-9441-02
Apr 17, 2027
GlyxeraSitagliptin (As Phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Importer: Firmlink Pharma Phils., Co.
DR-XY47827
Mar 17, 2027
GlyxeraSitagliptin (As Phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Firmlink Pharma Phils., Co.
DR-XY48383
Sep 30, 2027
Instadip 100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.Importer: Sun Pharma Philippines, Inc
DRP-12951
Nov 8, 2027
Instadip 25Sitagliptin (as phosphate)
25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines Inc.
DRP-13859
May 11, 2028
Instadip 50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister pack of 10 Tablets (Box of 30's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-12978
Nov 11, 2027
JanogenSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc.
DRP-13646-03
Mar 22, 2028
JanogenSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc.
DRP-13645-03
Mar 22, 2028
Januglip 100Sitagliptin (as phosphate)
100 mg TabletAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc.
DRP-10623-02
Oct 28, 2031
JanuviaSitagliptin
100 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7's (as Physician's Sample) (Box of 7's)
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5944
Jan 28, 2030
JanuviaSitagliptin (as phosphate)
25 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's)
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5943
Jan 28, 2030
JANUVIASitagliptin
50 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s Box of 28's; In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) Box of 7's
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5945
Jan 28, 2030
JanuvisSitagliptin (as phosphate)
25 mg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK ENTERPRISES INC.
DRP-10625
Oct 28, 2031
JanuvisSitagliptin (as phosphate)
50 mg TabletAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Oxpharm IncImporter: AMB HK Enterprises Inc.
DRP-10624-04
Oct 28, 2031
Januvit 100Sitagliptin (as monohydrate phosphate)
100 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 60's)
RxVAT-exempt
SunGlow Lifesciences Private LimitedIndia
Despina Pharma Inc.
DRP-17956
Apr 15, 2031
Januvit 50Sitagliptin (as monohydrate phosphate)
50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 60's)
RxVAT-exempt
SunGlow Lifesciences Private LimitedIndia
Despina Pharma Inc.
DRP-17955
Apr 15, 2031
JentinSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's)
RxVAT-exempt
The Searle Company LimitedPakistan
Getz Bros. Philippines, Inc.
DR-XY49190
Sep 13, 2029
JentinSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's)
RxVAT-exempt
The Searle Company LimitedPakistan
Getz Bros. Philippines, Inc.
DR-XY49189
Sep 13, 2029
Jestaglip 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Boon Pharma Corp.Importer: Orange Biotec Inc.
DRP-12919-02
Oct 28, 2027
Jestaglip 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Boon Pharma Corp.Importer: Orange Biotec Inc.
DRP-14689-03
Nov 23, 2028
KoztaSitagliptin (as hydrochloride monohydrate)
100 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sag Manufacturing, S.L.U.Spain
UNILAB, Inc.
DRP-15217
May 29, 2029
KoztaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
UNILAB, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8900-04
Jun 8, 2030
KoztaSitagliptin (as hydrochloride monohydrate)
25 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sag Manufacturing, S.L.U.Spain
UNILAB, Inc
DRP-16881
Aug 29, 2030
KoztaSitagliptin (as hydrochloride monohydrate)
50 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Sag Manufacturing, S.L.U.Spain
UNILAB, Inc
DRP-16880
Aug 29, 2030
KoztaSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Unilab, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8901-04
Jun 8, 2030
LupigliptinSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Medspecialty, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-7108-01
Apr 20, 2031
LupigliptinSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Medspecialty, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-9441-01
Apr 17, 2027
MedliptinSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-16354
Feb 18, 2030
MedliptinSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private Limited.India
Medethix, Inc.
DRP-16355
Feb 18, 2030
NoneSitagliptin (as phosphate)
100 mg Film Coated TabletAlu/PVC blister pack x 7's (Box of 4 blister packs x 7 tablets)
RxVAT-exempt
Novagen Healthcare LimitedIndia
Medethix, Inc.
DRP-18954
Oct 6, 2031
NoneSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-13646-05
Mar 22, 2028
NoneSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-16354-02
Feb 18, 2030
NoneSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceutical LimitedIndia
Actimed, Inc.Importer: Medethix, Inc.
DRP-6382-04
Oct 9, 2030
NoneSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAluminum/Aluminum Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7128-02
Apr 20, 2031
NoneSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8900
Jun 8, 2030
NoneSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8900-01
Jun 8, 2030
NoneSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-9079-05
Oct 31, 2030
NoneSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-9079-06
Oct 31, 2030
NoneSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletsAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Reta DrugImporter: Orange Biotec Inc.
DRP-12919-01
Oct 28, 2027
NoneSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc.
DPR-16383-02
Feb 28, 2030
NoneSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-13645-05
Mar 22, 2028
NoneSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Reta DrugImporter: Orange Biotec Inc.
DRP-14689-01
Nov 23, 2028
NoneSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
Actimed, Inc.Importer: Medethix, Inc.
DRP-6383-04
Oct 9, 2030
NoneSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8901-01
Jun 8, 2030
NoneSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Reta DrugImporter: Ambica International Corporation
DRP-9031-02
Aug 18, 2030
NoneSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-9078-02
Oct 31, 2030
NoneSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-9078-03
Oct 31, 2030
NoneSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
South Star DrugImporter: Ambica International Corporation
DRP-9078-08
Oct 31, 2030
philsitz-100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-12289-01
Jul 8, 2027
Philsitz-50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-12290-01
Jul 8, 2027
PremiliptinSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-13265-01
Jan 18, 2028
ProgliptinSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceutical LimitedIndia
Prebiotech Advanced Pharma Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-8334-02
Aug 15, 2029
Si2normSitagliptin (As Phosphate Monohydrate)
100 mg Film Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Suhitas Pharmaceuticals, Inc.
DRP-12919
Oct 28, 2027
Si2normSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt., Ltd.Nepal
Suhitas Pharmaceuticals Inc
DRP-14689
Nov 23, 2028
Silaptaen 100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-7316
Sep 11, 2027
Silaptaen 50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-7315
Sep 11, 2027
SitadinSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
Trader: Medchoice Endocrine Group, Inc.
DRP-13837
Apr 27, 2028
SitadinSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
Trader: Medchoice Endocrine Group, Inc.
DRP-13761
Apr 13, 2028
Sitag-100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's; Alu/Alu Blister Pack x 10's Box of 50's
RxVAT-exempt
Bafna Pharmaceutical LimitedIndia
MedEthix, Inc.
DRP-6382
Oct 9, 2030
Sitag-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 50's)
RxVAT-exempt
Bafna Pharmaceuticals LimitedIndia
MedEthix, Inc.
DRP-6383
Oct 9, 2030
SitagenSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc.
DRP-13646-01
Mar 22, 2028
SitagenSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc.
DRP-13645-01
Mar 22, 2028
Sitagli-100Sitagliptin
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Ambica International Corporation
DRP-11457
Mar 16, 2032
Sitagli-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Ambica International Corporation
DRP-9031
Aug 18, 2030
SitagligoSitagliptin
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-11457-01
Mar 16, 2037
SitagligoSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation
DRP-9031-01
Aug 18, 2030
SitaglinexSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Ambica International Corporation
DRP-12316
Jul 13, 2032
SitaglinexSitagliptin (As Phosphate)
25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Ambica International Corporation
DRP-12318
Jul 14, 2027
SitaglinexSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Ambica International Corporation
DRP-12317
Jul 14, 2027
Sitaglisaph-100Sitagliptin (As Phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-13116
May 18, 2031
Sitaglisaph-50Sitagliptin (As Phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-13117
May 18, 2031
SitaglizenSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Janamed CorporationImporter: Pharmakon Biotec Inc.
DRP-13646-04
Mar 22, 2028
SitaglizenSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Janamed CorporationImporter: Pharmakon Biotec Inc.
DRP-13645-04
Mar 22, 2028
Sitaglux 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutiucal Inc.
DRP-16382-01
Feb 28, 2030
Sitaglux 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-16383-01
Feb 28, 2030
SitagpinaSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu blister pack x 10's Box of 30's
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Pharmastar Int'l Trading Corp.
DRP-8334
Aug 15, 2029
Sitagral-50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu / Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-9031-03
Aug 18, 2030
Sitagram-100Sitagliptin
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-11457-03
Mar 16, 2032
SitagrichSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Medirich Pharma Distribution Corp.Importer: Orange Biotec Inc.
DRP-14689-02
Nov 23, 2028
Sitaguard 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-12958-01
Nov 9, 2027
Sitaguard 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-8352-01
Aug 28, 2029
SitakemSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu-Alu blister pack x 10's Box of 30's
RxVAT-exempt
Rhydburg Pharmaceutical Ltd.India
Alkem Laboratories CorporationImporter: Genedrift Philippines OPC
DRP-7316-01
Sep 11, 2027
SitakemSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Alkem Laboratories CorporationImporter: Genedrift Philippines OPC
DRP-7315-01
Sep 11, 2027
Sitalia 100Sitagliptin (as monohydrate phosphate)
100 mg Film Coated Tablet
RxVAT-exempt
Delta Pharma Ltd.Bangladesh
Biomed Pharma Inc.
DRP-17596
Feb 6, 2031
Sitallion 100Sitagliptin ( as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private Limitedlridia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-16354-01
Feb 18, 2030
Sitallion 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-16355-01
Feb 18, 2030
Sitamac 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY48544
Jan 3, 2028
Sitamac 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY48543
Jan 3, 2028
SitaphilSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Phil Asia Pharma IncImporter: Ambica International Corporation
DRP-9079-02
Oct 31, 2030
SitaphilSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Phil Asia Pharma IncImporter: Ambica International Corporation
DRP-9078-06
Oct 31, 2030
SitaproSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-7108
Apr 20, 2031
SitaproSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Transcend Phils., Inc.
DRP-9441
Apr 17, 2027
Sitarox-100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Roxwester International Corp.Importer: Pharmakon Biotec Inc.
DRP-13646-08
Mar 22, 2028
Sitarox-50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India 174101
Roxwester International Corp.Importer: Pharmakon Biotec Inc.
DRP-13645-08
Mar 22, 2028
Sitastar-100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc.
DRP-13116-01
Dec 2, 2027
Sitastar-50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc.
DRP-13117-01
Dec 2, 2027
Sitathyst 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc.
DRP-16355-02
Feb 18, 2030
Sitatin 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Limited
DR-XY48592
Jan 31, 2028
Sitatin 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Limited.India
VE Pharma Inc.Trader: Vexxa Lifesciences Limited
DR-XY48591
Jan 31, 2028
Sitavia 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) x 10's (Box of 30's)
RxVAT-exempt
Korea United Pharm., Int'l Jsc.Vietnam
United Douglas Pharm Philippines, Inc.
DR-XY48531
Dec 14, 2027
Sitavia 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Korea United Pharm., Int'l Jsc.Vietnam
United Douglas Pharm Philippines, Inc.
DR-XY48530
Dec 14, 2027
Sitazit 100Sitagliptin (As Hydrochloride)
100 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Hetero Labs Limited, Unit VIndia
Camber Pharmaceuticals, Inc.
DR-XY48546
Dec 29, 2027
Sitazit 25Sitagliptin (As Hydrochloride)
25 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Hetero Labs Limited, Unit VIndia
Camber Pharmaceuticals, Inc.
DR-XY48547
Dec 29, 2027
Sitazit 50Sitagliptin (As Hydrochloride)
50 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Hetero Labs Limited, Unit VIndia
Camber Pharmaceuticals, Inc.
DR-XY48548
Dec 29, 2027
SitazucaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DR-XY49413
Jun 10, 2030
SitazucaSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DR-XY49414
Jun 10, 2030
SitfarSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack of 3 x 10 Tablets (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-13646
Mar 22, 2028
SitfarSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-13645
Mar 22, 2028
Sitodol 100Sitagliptin (as phosphate monohydrate)
100mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16131
Nov 7, 2029
Sitodol 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16022
Feb 11, 2030
Sitplixin 100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
HealthPrescription, Inc.Importer: Ambica International Corporation
DRP-9079-04
Oct 31, 2030
Sitplixin 50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
HealthPrescription, Inc.Importer: Ambica International Corporation
DRP-9078-05
Oct 31, 2030
SitzeaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13646-06
Mar 22, 2028
SitzeaSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-13645-06
Mar 22, 2028
Sunglip 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16107
Oct 30, 2029
Sunglip 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Limited.India
Genedrift Philippines OPC
DRP-16108
Oct 30, 2029
SytaGet 50Sitagliptin (as monohydrate phosphate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 14’s (Box of 28’s)
RxVAT-exempt
Sain Medicaments Pvt. Ltd.India
2MG Incorporated
DRP-18138
May 13, 2031
TaglipinSitagliptin
100 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16597-02
May 13, 2030
TaglisydSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/PVDC Blister White Opaque x 10’s (Box of 100 tablets)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-13854
May 3, 2028
TaglisydSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-13839
Apr 27, 2028
TaglisydSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-13840
Apr 27, 2028
TiglipzaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets)
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.India
Lakeside Pharmaceuticals Phil., Inc.Importer: Pharmakon Biotec Inc.
DRP-13646-02
Mar 22, 2028
TiglipzaSitagliptin (as phosphate)
50 mg Film-Coated Tablet
RxVAT-exempt
Magbro Healthcare Pvt. Ltd.
Lakeside Pharmaceuticals Phil., Inc.Importer: Pharmakon Biotec Inc.
DRP-13645-02
Mar 22, 2028
Torsit 100Sitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48589
Jan 30, 2028
Torsit 100Sitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-9079-07
Oct 31, 2030
Torsit 25Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48587
Jan 30, 2028
Torsit 50Sitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48588
Jan 30, 2028
Torsit 50Sitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-9078-07
Oct 31, 2030
TreviaSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) Alu/Alu Blister Pack x 1's (Physician sample) (Box of 1's)
RxVAT-exempt
Getz Pharma (Pvt.) Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY47530
Sep 9, 2030
TreviaSitagliptin (as phosphate)
50 mg Film-coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) Alu/Alu Blister Pack x 1's (Physician sample) (Box of 1's)
RxVAT-exempt
Getz Pharma (Pvt.) Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY47529
Sep 9, 2030
UnbrandedSitagliptin
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
Reta DrugImporter: Ambica International Corporation
DRP-11457-02
Mar 16, 2032
UnbrandedSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Trader: Gamot Philippines, Inc.
DRP-12503
Aug 26, 2032
UnbrandedSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Euro-Health Care Exponents, Inc.
DRP-11159
Feb 8, 2037
UnbrandedSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Malolos Bulacan
Trader: Metz Pharmaceuticals, Inc.
DRP-11198
Feb 11, 2032
UnbrandedSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-11202
Feb 11, 2032
UnbrandedSitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Medspecialty, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7127-04
Apr 20, 2031
UnbrandedSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Watsons Personal Care Stores (Philippines), Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7129-02
Apr 20, 2031
UnbrandedSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Medspecialty, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-7129-05
Apr 20, 2031
UnbrandedSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's)
RxVAT-exempt
Sai Mirra Innopharm Pvt. Ltd.India
Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd.
DRP-8901
Jun 8, 2030
VilantraSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Oxpharm Inc.Importer: AMB HK ENTERPRISES INC.
DRP-10623
Oct 28, 2031
VilantraSitagliptin (as phosphate)
50 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Oxpharm Inc.Importer: AMB HK Enterprises Inc.
DRP-10624
Oct 28, 2031
VolreaSitagliptin (as phosphate monohydrate)
100mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's )
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12845
Oct 18, 2027
XeleviaSitagliptin (as phosphate)
100 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) (Box of 7's)
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5944-01
Jan 28, 2030
XeleviaSitagliptin
25 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box x 28's)
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5943-01
Jan 28, 2030
XeleviaSitagliptin
50 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) (Box of 7's)
RxVAT-exempt
Organon Pharma (UK) LimitedUnited Kingdom
Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-5945-01
Jan 28, 2030
XglipSitagliptin (as phosphate monohydrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16996
Sep 12, 2030
XglipSitagliptin (as phosphate monohydrate)
50 mg Film Coated TabletAlu/Alu blister Pack x 10's (Box of 100's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-17169
Oct 10, 2030
XiglipSitagliptin (as phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises, Inc.
DRP-12289-03
Jul 8, 2027
XigtalptnSitagliptin
100 mg Film-coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's & 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16597
May 13, 2030
Xigtalptn 25Sitagliptin (as Phosphate)
25 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's and 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.,Philippines
—
DRP-19033
Oct 19, 2031
Xigtalptn 50Sitagliptin (as Phosphate)
50 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's and 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.,Philippines
—
DRP-19027
Oct 19, 2031
Xordim-50Sitagliptin (as phosphate)
50 mg Film Coated TabletAlu/Alu Blister pack of 10's (Box of 100's)
RxVAT-exempt
Innovative HealthcareIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment And Supplies Trading
DRP-18404
Jul 2, 2031
Zincretin 100Sitagliptin (as phosphate)
100 mg Film Coated TabletAlu-Alu blister pack x 10's (Box of 1 blister pack x 10 tablets physician sample; Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-13290
Jan 18, 2028
Zincretin 50Sitagliptin
50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-14085
Jun 23, 2028
Zita 100Sitagliptin
100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-14083
Jun 23, 2028
Zita 50Sitagliptin
50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample
RxVAT-exempt
Zydus Lifesciences Limited.India
Zydus Healthcare Philippines Inc.
DRP-14084
Jun 23, 2028
ZytacareSitagliptin (as phosphate monohydrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
National Healthcare Pvt. Ltd.Nepal
Medcare PharmaceuticalsImporter: Orange Biotec Inc.
DRP-14689-04
Nov 23, 2028
(no brand name)Sitagliptin (as Phosphate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DRP-12502
Aug 26, 2027
(no brand name)Sitagliptin (As Phosphate)
25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Beximco Pharmaceuticals Ltd.Bangladesh
Importer: Firmlink Pharma Phils., Co.
DR-XY47828
Mar 17, 2027
(no brand name)Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: D.B. Manix International, Inc.
DRP-11157
Feb 8, 2027
(no brand name)Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DRP-11158
Feb 8, 2027
(no brand name)Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-11161
Feb 8, 2027
(no brand name)Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-11197
Feb 11, 2027
(no brand name)Sitagliptin (as Phosphate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DRP-11199
Feb 11, 2027
(no brand name)Sitagliptin (as Phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DRP-11200
Feb 11, 2027
(no brand name)Sitagliptin (as Phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-11201
Feb 11, 2027
(no brand name)Sitagliptin (as phosphate monohydrate)
25 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-14771
Jan 2, 2029
(no brand name)Sitagliptin (as phosphate monohydrate)
50 mg Film C Oated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's)
RxVAT-exempt
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-16356
Feb 18, 2030
(no brand name)Sitagliptin (as Phosphate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-12504
Aug 26, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 100 mg tablets are beige, round, film-coated tablets with "277" on one side. 50 mg tablets are light beige, round, film-coated tablets with "112" on one side. 25 mg tablets are pink, round, film-coated tablets with "221" on one side. Tablets: 100 mg, 50 mg, and 25 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA. (5.1)
  • Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JANUVIA in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. (5.2)
  • Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. (5.3)
  • Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required. (5.4, 7.1)
  • Hypersensitivity Reactions: There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with JANUVIA such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Promptly stop JANUVIA, assess for other potential causes, institute appropriate monitoring and treatment. (5.5, 6.2)
  • Severe and Disabling Arthralgia: Has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for …
5.1 Pancreatitis

5.1 Pancreatitis There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiation of JANUVIA, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, JANUVIA should promptly be discontinued and appropriate management should be initiated.

It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA.

5.2 Heart Failure

5.2 Heart Failure An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JANUVIA prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy.

Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUVIA.

5.3 Acute Renal Failure

5.3 Acute Renal Failure There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal impairment, some of whom were prescribed inappropriate doses of sitagliptin. A return to baseline levels of renal impairment has been observed with supportive treatment and discontinuation of potentially causative agents.

Consideration can be given to cautiously reinitiating JANUVIA if another etiology is deemed likely to have precipitated the acute worsening of renal function. Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with ESRD requiring hemodialysis or peritoneal dialysis. [See Dosage and Administration (2.2); Use in Specific Populations (8.6).]

5.4 Hypoglycemia with Concomitant Use with Insulin

5.4 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues When JANUVIA was used in combination with insulin or insulin secretagogues (e.g., sulfonylurea), medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. [See Adverse Reactions (6.1).] Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia. [See Drug Interactions (7.1).]

5.5 Hypersensitivity Reactions

5.5 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose.

If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes. [See Adverse Reactions (6.2).] Angioedema has also been reported with other DPP-4 inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.

5.6 Severe and Disabling Arthralgia

5.6 Severe and Disabling Arthralgia There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication.

A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

5.7 Bullous Pemphigoid

5.7 Bullous Pemphigoid Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving JANUVIA.

If bullous pemphigoid is suspected, JANUVIA should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.

Drug interactions

Drug or classSeverityEffectWhat to do
Insulin or insulin secretagogues (e.g., sulfonylureas)Adjust or monitorMore hypoglycemia.Lower insulin or secretagogue doses may be needed.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.

Sitagliptin is also a substrate of P-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin.

However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin.

Drug Interaction Studies In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4.

Sitagliptin is a P-gp substrate, but does not inhibit P-gp mediated transport of digoxin.

In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraceptive (ethinyl estradiol and norethindrone) (Table 4), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT).

Adverse reactions

Common

  • Upper respiratory tract infection, nasopharyngitis, headache (≥5% and more than placebo)

Serious

  • Acute pancreatitis
  • Heart failure (DPP-4 inhibitor association)
  • Acute renal failure, sometimes requiring dialysis (postmarketing)
  • Hypoglycemia with insulin or secretagogues
  • Serious hypersensitivity (anaphylaxis, angioedema, exfoliative skin reactions)
  • Severe and disabling arthralgia
  • Bullous pemphigoid
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis [see Warnings and Precautions (5.1)] Heart Failure [see Warnings and Precautions (5.2)] Acute Renal Failure [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.4)] Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.6)] Bullous Pemphigoid [see Warnings and Precautions (5.7)] Adverse reactions reported in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache. In the add-on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with JANUVIA compared to placebo. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In controlled clinical studies as both monotherapy and combination therapy with metformin, pioglitazone, or rosiglitazone and metformin, the overall incidence of adverse reactions, hypoglycemia, and discontinuation of therapy due to clinical adverse reactions with JANUVIA were similar to placebo.

In combination with glimepiride, with or without metformin, the overall incidence of clinical adverse reactions with JANUVIA was higher than with placebo, in part related to a higher incidence of hypoglycemia (see Table 3); the incidence of discontinuation due to clinical adverse reactions was similar to placebo. Two placebo-controlled monotherapy studies, one of 18- and one of 24-week duration, included patients treated with JANUVIA 100 mg daily, JANUVIA 200 mg daily, and placebo.

Five placebo-controlled add-on combination therapy studies were also conducted: one with metformin; one with pioglitazone; one with metformin and rosiglitazone; one with glimepiride (with or without metformin); and one with insulin (with or without metformin). In these trials, patients with inadequate glycemic control on a stable dose of the background therapy were randomized to add-on therapy with JANUVIA 100 mg daily or placebo.

The adverse reactions, excluding hypoglycemia, reported regardless of investigator assessment of causality in ≥5% of patients treated with JANUVIA 100 mg daily and more commonly than in patients treated with placebo, are shown in Table 1 for the clinical trials of at least 18 weeks duration. Incidences of hypoglycemia are shown in Table 3.

Table 1: Placebo-Controlled Clinical Studies of JANUVIA Monotherapy or Add-on Combination Therapy with Pioglitazone, Metformin + Rosiglitazone, or Glimepiride +/- Metformin: Adverse Reactions (Excluding Hypoglycemia) Reported in ≥5% of Patients and More Commonly than in Patients Given Placebo, Regardless of Investigator Assessment of Causality Intent-to-treat population Number of Patients (%) Monotherapy (18 or 24 weeks) JANUVIA 100 mg Placebo N = 443 N = 363 Nasopharyngitis 23 (5.2) 12 (3.3) Combination with Pioglitazone (24 weeks) JANUVIA 100 mg + Pioglitazone Placebo + Pioglitazone N = 175 N = 178 Upper Respiratory Tract Infection 11 (6.3) 6 (3.4) Headache 9 (5.1) 7 (3.9) Combination with Metformin + Rosiglitazone (18 weeks) JANUVIA 100 mg + Metformin + Rosiglitazone Placebo + Metformin + Rosiglitazone N = 181 N = 97 Upper Respiratory Tract Infection 10 (5.5) 5 (5.2) Nasopharyngitis 11 (6.1) 4 (4.1) Combination with Glimepiride (+/- Metformin) (24 weeks) JANUVIA 100 mg + Glimepiride (+/- Metformin) Placebo + Glimepiride (+/- Metformin) N = 222 N = 219 Nasopharyngitis 14 (6.3) 10 (4.6) Headache 13 (5.9) 5 (2.3) In the 24-week study of patients receiving JANUVIA as add-on combination therapy with metformin, there were no adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo. In the 24-week study of patients receiving JANUVIA as add-on therapy to insulin (with or without metformin), there were no adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo, except for hypoglycemia (see Table 3).

In the study of JANUVIA as add-on combination therapy with metformin and rosiglitazone (Table 1), through Week 54 the adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo were: upper respiratory tract infection (JANUVIA, 15.5%; placebo, 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%, 4.1%). In a pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the incidence of selected gastrointestinal adverse reactions in patients treated with JANUVIA was as follows: abdominal pain (JANUVIA 100 mg, 2.3%; placebo, 2.1%), nausea (1.4%, 0.6%), and diarrhea (3.0%, 2.3%).

In an additional, 24-week, placebo-controlled factorial study of initial therapy with sitagliptin in combination with metformin, the adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients are shown in Table 2. Table 2: Initial Therapy with Combination of Sitagliptin and Metformin: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Metformin alone, Sitagliptin alone, and Placebo) Intent-to-treat population.

Number of Patients (%) Placebo Sitagliptin (JANUVIA) 100 mg QD Metformin HCl 500 or 1000 mg bid Data pooled for the patients given the lower and higher doses of metformin. Sitagliptin 50 mg bid + Metformin HCl 500 or 1000 mg bid N = 176 N = 179 N = 364 N = 372 Upper Respiratory Infection 9 (5.1) 8 (4.5) 19 (5.2) 23 (6.2) Headache 5 (2.8) 2 (1.1) 14 (3.8) 22 (5.9) In a 24-week study of initial therapy with JANUVIA in combination with pioglitazone, there were no adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients and more commonly than in patients given pioglitazone alone.

No clinically meaningful changes in vital signs or in ECG (including in QTc interval) were observed in patients treated with JANUVIA. In a pooled analysis of 19 double-blind clinical trials that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of acute pancreatitis was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sitagliptin and 4 patients with an event in 3942 patient-years for control).

Hypoglycemia In the above studies (N=9), adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia. A concurrent blood glucose measurement was not required although most (74%) reports of hypoglycemia were accompanied by a blood glucose measurement ≤70 mg/dL. When JANUVIA was coadministered with a sulfonylurea or with insulin, the percentage of patients with at least one adverse reaction of hypoglycemia was higher than in the corresponding placebo group (Table 3).

Table 3: Incidence and Rate of Hypoglycemia Adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population. in Placebo-Controlled Clinical Studies when JANUVIA was used as Add-On Therapy to Glimepiride (with or without Metformin) or Insulin (with or without Metformin), Regardless of Investigator Assessment of Causality Add-On to Glimepiride (+/- Metformin) (24 weeks) JANUVIA 100 mg + Glimepiride (+/- Metformin) Placebo + Glimepiride (+/- Metformin) N = 222 N = 219 Overall (%) 27 (12.2) 4 (1.8) Rate (episodes/patient-year) Based on total number of events (i.e., a single patient may have had multiple events). 0.59 0.24 Severe (%) Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure. 0 (0.0) 0 (0.0) Add-On to Insulin (+/- Metformin) (24 weeks) JANUVIA 100 mg + Insulin (+/- Metformin) Placebo + Insulin (+/- Metformin) N = 322 N = 319 Overall (%) 50 (15.5) 25 (7.8) Rate (episodes/patient-year) 1.06 0.51 Severe (%) 2 (0.6) 1 (0.3) In a pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the overall incidence of adverse reactions of hypoglycemia was 1.2% in patients treated with JANUVIA 100 mg and 0.9% in patients treated with placebo. In the study of JANUVIA as add-on combination therapy with metformin and rosiglitazone, the overall incidence of hypoglycemia was 2.2% in patients given add-on JANUVIA and 0.0% in patients given add-on placebo through Week 18.

Through Week 54, the overall incidence of hypoglycemia was 3.9% in patients given add-on JANUVIA and 1.0% in patients given add-on placebo. In the 24-week, placebo-controlled factorial study of initial therapy with JANUVIA in combination with metformin, the incidence of hypoglycemia was 0.6% in patients given placebo, 0.6% in patients given JANUVIA alone, 0.8% in patients given metformin alone, and 1.6% in patients given JANUVIA in combination with metformin.

In the study of JANUVIA as initial therapy with pioglitazone, one patient taking JANUVIA experienced a severe episode of hypoglycemia. There were no severe hypoglycemia episodes reported in other studies except in the study involving coadministration with insulin. In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement ≤70 mg/dL) did not differ between the sitagliptin and placebo groups.

Laboratory Tests Across clinical studies, the incidence of laboratory adverse reactions was similar in patients treated with JANUVIA 100 mg compared to patients treated with placebo. A small increase in white blood cell count (WBC) was observed due to an increase in neutrophils. This increase in WBC (of approximately 200 cells/microL vs placebo, in four pooled placebo-controlled clinical studies, with a mean baseline WBC count of approximately 6600 cells/microL) is not considered to be clinically relevant.

In a 12-week study of 91 patients with chronic renal insufficiency, 37 patients with moderate renal insufficiency were randomized to JANUVIA 50 mg daily, while 14 patients with the same magnitude of renal impairment were randomized to placebo. Mean (SE) increases in serum creatinine were observed in patients treated with JANUVIA [0.12 mg/dL (0.04)] and in patients treated with placebo [0.07 mg/dL (0.07)].

The clinical significance of this added increase in serum creatinine relative to placebo is not known.

6.2 Postmarketing Experience

6.2 Postmarketing Experience Additional adverse reactions have been identified during postapproval use of JANUVIA as monotherapy and/or in combination with other antihyperglycemic agents. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions including Stevens-Johnson syndrome; hepatic enzyme elevations; acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis [see Indications and Usage (1)]; worsening renal function, including acute renal failure (sometimes requiring dialysis), and tubulointerstitial nephritis; severe and disabling arthralgia; bullous pemphigoid; constipation; vomiting; headache; myalgia; pain in extremity; back pain; pruritus; mouth ulceration; stomatitis; rhabdomyolysis.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Placebo-Controlled Clinical Studies of JANUVIA Monotherapy or Add-on Combination Therapy with Pioglitazone, Metformin + Rosiglitazone, or Glimepiride +/- Metformin: Adverse Reactions (Excluding Hypoglycemia) Reported in ≥5% of Patients and More Commonly than in Patients Given Placebo, Regardless of Investigator Assessment of CausalityIntent-to-treat population
Number of Patients (%)
Monotherapy (18 or 24 weeks)JANUVIA 100 mgPlacebo
N = 443N = 363
Nasopharyngitis23 (5.2)12 (3.3)
Combination with Pioglitazone (24 weeks)JANUVIA 100 mg +Pioglitazone Placebo +Pioglitazone
N = 175N = 178
Upper Respiratory Tract Infection11 (6.3)6 (3.4)
Headache9 (5.1)7 (3.9)
Combination with Metformin + Rosiglitazone (18 weeks)JANUVIA 100 mg + Metformin + Rosiglitazone Placebo + Metformin + Rosiglitazone
N = 181N = 97
Upper Respiratory Tract Infection10 (5.5)5 (5.2)
Nasopharyngitis11 (6.1)4 (4.1)
Combination with Glimepiride (+/- Metformin) (24 weeks)JANUVIA 100 mg + Glimepiride (+/- Metformin)Placebo+ Glimepiride(+/- Metformin)
N = 222N = 219
Nasopharyngitis14 (6.3)10 (4.6)
Headache13 (5.9)5 (2.3)
Table 2: Initial Therapy with Combination of Sitagliptin and Metformin: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Metformin alone, Sitagliptin alone, and Placebo)Intent-to-treat population.
Number of Patients (%)
PlaceboSitagliptin (JANUVIA) 100 mg QDMetformin HCl500 or 1000 mg bidData pooled for the patients given the lower and higher doses of metformin.Sitagliptin50 mg bid +Metformin HCl500 or 1000 mg bid
N = 176N = 179N = 364N = 372
Upper Respiratory Infection9 (5.1)8 (4.5)19 (5.2)23 (6.2)
Headache5 (2.8)2 (1.1)14 (3.8)22 (5.9)
Table 3: Incidence and Rate of HypoglycemiaAdverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population. in Placebo-Controlled Clinical Studies when JANUVIA was used as Add-On Therapy to Glimepiride (with or without Metformin) or Insulin (with or without Metformin), Regardless of Investigator Assessment of Causality
Add-On to Glimepiride (+/- Metformin) (24 weeks)JANUVIA 100 mg+ Glimepiride(+/- Metformin)Placebo+ Glimepiride(+/- Metformin)
N = 222N = 219
Overall (%)27 (12.2)4 (1.8)
Rate (episodes/patient-year)Based on total number of events (i.e., a single patient may have had multiple events).0.590.24
Severe (%)Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure.0 (0.0)0 (0.0)
Add-On to Insulin (+/- Metformin) (24 weeks)JANUVIA 100 mg+ Insulin(+/- Metformin)Placebo+ Insulin(+/- Metformin)
N = 322N = 319
Overall (%)50 (15.5)25 (7.8)
Rate (episodes/patient-year)1.060.51
Severe (%)2 (0.6)1 (0.3)

Monitoring parameters

  • Assess kidney function before starting and periodically (label). Pancreatitis, hypoglycemia with sulfonylureas or insulin. Kidney
  • Kidney function before starting and periodically (dose by eGFR)
  • Symptoms of pancreatitis
  • Signs of heart failure in at-risk patients
  • Glycemic control
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The limited available data with JANUVIA in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. No adverse developmental effects were observed when sitagliptin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 30-times and 20-times, respectively, the 100 mg clinical dose, based on AUC [see Data].

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a Hemoglobin A1c >7% and has been reported to be as high as 20-25% in women with a Hemoglobin A1c >10%. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.

Data Animal Data In embryo-fetal development studies, sitagliptin administered to pregnant rats and rabbits during organogenesis (gestation day 6 to 20) did not adversely affect developmental outcomes at oral doses up to 250 mg/kg (30-times the 100 mg clinical dose) and 125 mg/kg (20-times the 100 mg clinical dose), respectively, based on AUC. Higher doses in rats associated with maternal toxicity increased the incidence of rib malformations in offspring at 1000 mg/kg, or approximately 100-times the clinical dose, based on AUC.

Placental transfer of sitagliptin was observed in pregnant rats and rabbits. Sitagliptin administered to female rats from gestation day 6 to lactation day 21 caused no functional or behavioral toxicity in offspring of rats at doses up to 1000 mg/kg.

Mechanism of action

12.1 Mechanism of Action Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones.

Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis.

When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.

Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics General In patients with type 2 diabetes mellitus, administration of sitagliptin led to inhibition of DPP-4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP-4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness of insulin release to glucose, resulting in higher C-peptide and insulin concentrations.

The rise in insulin with the decrease in glucagon was associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal. In studies with healthy subjects, sitagliptin did not lower blood glucose or cause hypoglycemia. Sitagliptin and Metformin hydrochloride Coadministration In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents.

Coadministration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. Sitagliptin, but not metformin, increased active GIP concentrations. It is unclear how these findings relate to changes in glycemic control in patients with type 2 diabetes mellitus. Cardiac Electrophysiology In a randomized, placebo-controlled crossover study, 79 healthy subjects were administered a single oral dose of sitagliptin 100 mg, sitagliptin 800 mg (8 times the recommended dose), and placebo.

At the recommended dose of 100 mg, there was no effect on the QTc interval obtained at the peak plasma concentration, or at any other time during the study. Following the 800 mg dose, the maximum increase in the placebo-corrected mean change in QTc from baseline was observed at 3 hours postdose and was 8.0 msec. This increase is not considered to be clinically significant.

At the 800 mg dose, peak sitagliptin plasma concentrations were approximately 11 times higher than the peak concentrations following a 100-mg dose. In patients with type 2 diabetes mellitus administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration.

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 87%
Time to peak1 to 4 hours
Half-lifeAbout 12.4 hours
Half-life in kidney failure (ESKD) kidneyNot reported; AUC about 4-fold higher in severe impairment including ESRD on hemodialysis (label)
Volume of distributionAbout 198 L (Vss)
Protein binding38%
Metabolism (CYP, transporters)Minor (about 16% as metabolites); CYP3A4 with CYP2C8
Active metabolitesNone (trace metabolites)
Renal excretion kidneyAbout 79% unchanged in urine (active tubular secretion; OAT3, P-gp)
Dialyzability kidneyModestly: about 13.5% removed over a 3- to 4-hour hemodialysis; PD removal unknown (label).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 nM, and apparent terminal half-life (t 1/2 ) was 12.4 hours.

Elimination Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination.

The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min.

Metabolism Following a [ 14 C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin.

Excretion Following administration of an oral [ 14 C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of sitagliptin have been extensively characterized in healthy subjects and patients with type 2 diabetes mellitus. Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 nM, and apparent terminal half-life (t 1/2) was 12.4 hours.

Plasma AUC of sitagliptin increased in a dose-proportional manner and increased approximately 14% following 100 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject coefficients of variation for sitagliptin AUC were small (5.8% and 15.1%). The pharmacokinetics of sitagliptin was generally similar in healthy subjects and in patients with type 2 diabetes mellitus.

Absorption After oral administration of a 100 mg dose to healthy subjects, sitagliptin was rapidly absorbed with peak plasma concentrations (median T max) occurring 1 to 4 hours postdose. The absolute bioavailability of sitagliptin is approximately 87%. Effect of Food Coadministration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics of sitagliptin.

Distribution The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%). Elimination Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination.

The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Metabolism Following a [14 C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin.

In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8. Excretion Following administration of an oral [14 C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing.

Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established.

Sitagliptin is also a substrate of P-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin. However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin. Specific Populations Patients with Renal Impairment An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment, including patients with ESRD on hemodialysis, as compared to normal healthy control subjects.

Patients with Hepatic Impairment In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and C max of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin. These differences are not considered to be clinically meaningful.

There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score >9). Effects of Age, Body Mass Index (BMI), Gender, and Race Based on a population pharmacokinetic analysis or a composite analysis of available pharmacokinetic data, BMI, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of sitagliptin.

When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.

Drug Interaction Studies In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a P-gp substrate, but does not inhibit P-gp mediated transport of digoxin. Based on these results, sitagliptin is considered unlikely to cause interactions with other drugs that utilize these pathways.

Sitagliptin is not extensively bound to plasma proteins. Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low. In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraceptive (ethinyl estradiol and norethindrone) (Table 4), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT).

Table 4: Effect of Sitagliptin on Systemic Exposure of Coadministered Drugs Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified. Dose of Sitagliptin Geometric Mean Ratio (ratio with/without sitagliptin) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified.

C max Digoxin 0.25 mg Multiple dose. once daily for 10 days 100 mg once daily for 10 days Digoxin 1.11 AUC 0-24hr. 1.18 Glyburide 1.25 mg 200 mg once daily for 6 days Glyburide 1.09 1.01 Simvastatin 20 mg 200 mg once daily for 5 days Simvastatin 0.85 AUC 0-last. 0.80 Simvastatin Acid 1.12 1.06 Rosiglitazone 4 mg 200 mg once daily for 5 days Rosiglitazone 0.98 0.99 Warfarin 30 mg single dose on day 5 200 mg once daily for 11 days S(-) Warfarin 0.95 0.89 R(+) Warfarin 0.99 0.89 Ethinyl estradiol and norethindrone 21 days once daily of 35 µg ethinyl estradiol with norethindrone 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days 200 mg once daily for 21 days Ethinyl estradiol 0.99 0.97 Norethindrone 1.03 0.98 Metformin HCl 1000 mg twice daily for 14 days 50 mg twice daily for 7 days Metformin 1.02 AUC 0-12hr. 0.97 Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by coadministered medications (Table 5). Table 5: Effect of Coadministered Drugs on Systemic Exposure of Sitagliptin Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified.

Dose of Sitagliptin Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified. C max Cyclosporine 600 mg once daily 100 mg once daily Sitagliptin 1.29 1.68 Metformin HCl 1000 mg Multiple dose. twice daily for 14 days 50 mg twice daily for 7 days Sitagliptin 1.02 AUC 0-12hr. 1.05

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. JANUVIA · Merck Sharp & Dohme LLC [US FDA-approved label, version 71, November 14, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Merck Sharp & Dohme LLC. (2024). JANUVIA (sitagliptin) [Prescribing information; US FDA-approved label, NDA021995, set ID f85a48d0-0407-4c50-b0fa-7673a160bf01, version effective November 14, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01
  4. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .